{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T14:20:36Z","timestamp":1763389236326,"version":"3.41.2"},"reference-count":27,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,7,7]],"date-time":"2019-07-07T00:00:00Z","timestamp":1562457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100005790","name":"Thammasat University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005790","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Helicobacter"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Most therapies for <jats:italic>Helicobacter pylori<\/jats:italic> eradication utilize multiple drugs given 2\u20104 times daily. Patient adherence has been an impediment to reliably achieving high success. This study evaluated a once\u2010daily\u202fdosing <jats:italic>H\u00a0pylori<\/jats:italic> eradication\u202fregimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A prospective randomized pilot study of <jats:italic>H\u00a0pylori<\/jats:italic> eradication compared once\u2010daily treatment\u202fregimen containing levofloxacin (750\u00a0mg), clarithromycin\u2010MR (1\u00a0g), rabeprazole (60\u00a0mg), and bismuth subsalicylate (1,048\u00a0mg) for a 7 or 14\u00a0days. CYP2C19 genotype and antibiotic susceptibility tests were performed. Successful eradication was defined as negative 13C\u2010urea breath test at least 4\u00a0weeks after completion of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>100 subjects were randomized (40 men, 60 women with mean age =54\u00a0years). The eradication rates were as follows: 94% (47\/50; 95%CI 0.87\u20101.01) and 84% (42\/50; 95%CI 0.73\u20100.95) with 14\u2010day and 7\u2010day therapy (OR 0.34; 95%CI 0.08\u20101.35, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.06), respectively. Resistance rates were as follows: 13.0% for clarithromycin, 26.0% for fluoroquinolone, 2.9% for dual clarithromycin\u2010fluoroquinolone resistance, and 62.8% for metronidazole. The 14\u2010day regimen provided 100% eradication in patients with levofloxacin susceptible strain irrespective of the presence of clarithromycin resistance. CYP2C19 genotypes had no effect on cure rates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The once\u2010daily 14\u2010day rabeprazole\u2010, levofloxacin\u2010, clarithromycin\u2010MR\u2010, and bismuth\u2010containing therapy provided high eradication rate suggested that triple therapies with a PPI, bismuth, and clarithromycin\u2010MR or levofloxacin would be highly effective for once\u2010a\u2010day tailored therapy or as empiric therapy for first\u2010line regimen.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hel.12615","type":"journal-article","created":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T06:29:44Z","timestamp":1562567384000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Once\u2010daily rabeprazole, levofloxacin, clarithromycin\u2010MR, and bismuth for <i>Helicobacter pylori<\/i> eradication: A randomized study of 7 or 14 days (ONCE study)"],"prefix":"10.1111","volume":"24","author":[{"given":"Jeerayuth","family":"Auttajaroon","sequence":"first","affiliation":[{"name":"Gastroenterology Unit Thammasat University Hospital Pathumthani Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4298-9331","authenticated-orcid":false,"given":"Ratha\u2010korn","family":"Vilaichone","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit Thammasat University Hospital Pathumthani Thailand"},{"name":"National Digestive Diseases Research Center (NDRC) Pathumthani Thailand"},{"name":"Department of Medicine, Chulabhorn International College of Medicine (CICM) Thammasat University Pathumthani Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peranart","family":"Chotivitayatarakorn","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit Thammasat University Hospital Pathumthani Thailand"},{"name":"National Digestive Diseases Research Center (NDRC) Pathumthani Thailand"},{"name":"Department of Medicine, Chulabhorn International College of Medicine (CICM) Thammasat University Pathumthani Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varocha","family":"Mahachai","sequence":"additional","affiliation":[{"name":"National Digestive Diseases Research Center (NDRC) Pathumthani Thailand"},{"name":"Department of Medicine, Chulabhorn International College of Medicine (CICM) Thammasat University Pathumthani Thailand"},{"name":"Gastrointestinal and Liver Center Bangkok Medical Center  Bangkok Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,7,7]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2007.00518.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01393.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2011.06660.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2015.16.10.4353"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.10.024"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309252"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312288"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13911"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2006.03.004"},{"key":"e_1_2_7_11_1","first-page":"2839","article-title":"Effectiveness of 7\u2010day and 14\u2010day moxifloxacin\u2010dexlansoprazole based triple therapy and probiotic supplement for Helicobacter Pylori eradication in Thai patients with non\u2010ulcer dyspepsia: a double\u2010blind randomized placebo\u2010controlled study","volume":"18","author":"Chotivitayatarakorn P","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2014.10.003"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2011.00867.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.113959"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s005350170029"},{"key":"e_1_2_7_16_1","first-page":"363","article-title":"A review of rabeprazole in the treatment of acid\u2010related diseases","volume":"3","author":"Pace F","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2006.00799.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8463614"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.57"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.84a.14110"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.4103\/sjg.SJG_292_17"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.08.026"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.04.016"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.05.028"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.07.017"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00744-09"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02642-10"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12447"}],"container-title":["Helicobacter"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hel.12615","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hel.12615","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hel.12615","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T02:27:16Z","timestamp":1694226436000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hel.12615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,7]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1111\/hel.12615"],"URL":"https:\/\/doi.org\/10.1111\/hel.12615","archive":["Portico"],"relation":{},"ISSN":["1083-4389","1523-5378"],"issn-type":[{"type":"print","value":"1083-4389"},{"type":"electronic","value":"1523-5378"}],"subject":[],"published":{"date-parts":[[2019,7,7]]},"assertion":[{"value":"2019-02-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e12615"}}